Cardiovascular Disease

13
Pipeline Programs
17
Companies
20
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
1
0
1
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
133%
Monoclonal Antibody
133%
Small Molecule
133%
+ 17 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
LORCASERIN HYDROCHLORIDEApproved
lorcaserin hydrochloride
Unknown Company
oral
Amgen
REPATHAApproved
evolocumab
Amgen
PCSK9 Inhibitor [EPC]injection2015

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
1
EvolocumabPhase 4Monoclonal Antibody1 trial
AMG 890Phase 11 trial
Active Trials
NCT03626662Completed79Est. Apr 2023
NCT05284747Active Not Recruiting6,019Est. May 2027
Lantheus Medical Imaging
1 program
1
DEFINITY®Phase 41 trial
Active Trials
NCT00625365CompletedEst. Jul 2009
E
EisaiChina - Liaoning
1 program
1
Lorcaserin hydrochloridePhase 41 trial
Active Trials
NCT02019264Completed14,673Est. May 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
atorvastatinPhase 4Small Molecule1 trial
Active Trials
NCT00147602Completed4,732Est. Nov 2005
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
CagrilintidePhase 3Peptide1 trial
Active Trials
NCT05669755Active Not Recruiting7,101Est. Oct 2027
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
1
Whole yellow pea flourPhase 21 trial
Active Trials
NCT00839774CompletedEst. Mar 2008
BioLineRx
BioLineRxIsrael - Modi’in
1 program
1
BL-1040Phase 1/21 trial
Active Trials
NCT00557531UnknownEst. Jan 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
2
MidazolamPhase 11 trial
[14C]AZD5718 Oral SuspensionPhase 11 trial
Measurement of the Carotid Intima Media thicknessN/A1 trial
Active Trials
NCT00970918Completed2,609Est. Aug 2010
NCT04492709Completed14Est. Oct 2020
NCT03948451Completed6Est. Jul 2019
Bial
BialPortugal - Coronado
1 program
1
BIA 5-1058Phase 11 trial
Active Trials
NCT03489005CompletedEst. Oct 2018
Abbott
AbbottABBOTT PARK, IL
2 programs
Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)N/A1 trial
discharge vs. overnight stayN/A1 trial
Active Trials
NCT00933764Withdrawn0Est. Nov 2009
NCT01230606Completed303Est. Jun 2010
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
PATHwayN/A1 trial
chocolate consumption levelN/A1 trial
Active Trials
NCT02717806CompletedEst. Jul 2018
NCT03453073CompletedEst. Jul 2018
Elutia
ElutiaSILVER SPRING, MD
1 program
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) EnvelopeN/A1 trial
Active Trials
NCT02530970CompletedEst. Apr 2018
Rhythm Pharmaceuticals
1 program
Therapy Programming ReportN/A1 trial
Active Trials
NCT00856349Completed4,384Est. Mar 2013
Providence Therapeutics
1 program
Txt2PreventN/A1 trial
Active Trials
NCT02336919CompletedEst. Jan 2017
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
soy protein isolateN/A1 trial
Active Trials
NCT02024906WithdrawnEst. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AmgenEvolocumab
EisaiLorcaserin hydrochloride
Lantheus Medical ImagingDEFINITY®
Pfizeratorvastatin
Novo NordiskCagrilintide
Pulse BiosciencesWhole yellow pea flour
BioLineRxBL-1040
AstraZenecaMidazolam
AstraZeneca[14C]AZD5718 Oral Suspension
AmgenAMG 890
BialBIA 5-1058
City TherapeuticsPATHway
ElutiaA Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope
Providence TherapeuticsTxt2Prevent
Hamilton medicalsoy protein isolate

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 39,920 patients across 20 trials

NCT05284747AmgenEvolocumab

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Start: Oct 2022Est. completion: May 20276,019 patients
Phase 4Active Not Recruiting
NCT02019264EisaiLorcaserin hydrochloride

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Start: Jan 2014Est. completion: May 201814,673 patients
Phase 4Completed
NCT00625365Lantheus Medical ImagingDEFINITY®

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

Start: Feb 2008Est. completion: Jul 2009
Phase 4Completed
NCT00147602Pfizeratorvastatin

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Start: Nov 1998Est. completion: Nov 20054,732 patients
Phase 4Completed
NCT05669755Novo NordiskCagrilintide

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Start: Mar 2023Est. completion: Oct 20277,101 patients
Phase 3Active Not Recruiting
NCT00839774Pulse BiosciencesWhole yellow pea flour

Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors

Start: Feb 2007Est. completion: Mar 2008
Phase 2Completed
NCT00557531BioLineRxBL-1040

Safety and Feasibility of the Injectable BL-1040 Implant

Start: Mar 2008Est. completion: Jan 2014
Phase 1/2Unknown
NCT04492709AstraZenecaMidazolam

A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

Start: Jul 2020Est. completion: Oct 202014 patients
Phase 1Completed
NCT03948451AstraZeneca[14C]AZD5718 Oral Suspension

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Start: Apr 2019Est. completion: Jul 20196 patients
Phase 1Completed
NCT03626662AmgenAMG 890

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Start: Jul 2018Est. completion: Apr 202379 patients
Phase 1Completed
NCT03489005BialBIA 5-1058

Effect of BIA 5 1058 on Cardiac Repolarization

Start: Apr 2018Est. completion: Oct 2018
Phase 1Completed
NCT02717806City TherapeuticsPATHway

Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness

Start: Jun 2017Est. completion: Jul 2018
N/ACompleted
NCT02530970ElutiaA Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

Start: Oct 2015Est. completion: Apr 2018
N/ACompleted
NCT02336919Providence TherapeuticsTxt2Prevent

The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients

Start: Apr 2015Est. completion: Jan 2017
N/ACompleted
NCT02024906Hamilton medicalsoy protein isolate

Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants

Start: Feb 2015Est. completion: Sep 2015
N/AWithdrawn
NCT03453073City Therapeuticschocolate consumption level

Chocolate and CVD Risk in Postmenopausal Women

Start: Dec 2014Est. completion: Jul 2018
N/ACompleted
NCT00970918AstraZenecaMeasurement of the Carotid Intima Media thickness

Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs

Start: Oct 2009Est. completion: Aug 20102,609 patients
N/ACompleted
NCT00933764AbbottClinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)

Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)

Start: Aug 2009Est. completion: Nov 20090
N/AWithdrawn
NCT00856349Rhythm PharmaceuticalsTherapy Programming Report

Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming

Start: Apr 2009Est. completion: Mar 20134,384 patients
N/ACompleted
NCT01230606Abbottdischarge vs. overnight stay

Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention

Start: Jan 2008Est. completion: Jun 2010303 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
17 companies competing in this space